Phaseline

Companies › Shenzhen Shenxin Biotechnology

Shenzhen Shenxin Biotechnology: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 1; Infectious disease; next expected readout Apr 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Respiratory Syncytial Virus IN006 Bivalent mRNA Vaccine (IN006)
Bivalent mRNA vaccine targeting respiratory syncytial virus
RSVPhase 2Respiratory Syncytial Virus (RSV) Infection; Respiratory Syncytial Virus InfectionsApr 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06645665Respiratory Syncytial Virus IN006 Bivalent mRNA Vaccine (IN006)Phase 1Respiratory Syncytial Virus InfectionsInfectious diseaseApr 2027
NCT07128121Respiratory Syncytial Virus IN006 Bivalent mRNA Vaccine (IN006)Phase 2Respiratory Syncytial Virus (RSV) InfectionInfectious diseaseOct 2029

Targets

RSV (1)

Companies with the same targets

Sanofi ModernaTX AstraZeneca MAXVAX Biotechnology Limited Liability Company Enanta Pharmaceuticals GSK

Companies built like this

Biothervax OsteoRemedies Jiangsu ProteLight Pharmaceutical & Biotechnology MAXVAX Biotechnology Limited Liability Company Catalysis

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.